NCT07299331 2025-12-23
Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma
Zhengzhou University
Phase NA Not yet recruiting
Clinical Trials
9 trialsNCT07184424 2025-09-19
Lenalidomide
Beijing Tsinghua Chang Gung Hospital
Phase NA Completed
NCT06697483 2024-11-25
Risk Stratification and MRD-driven Maintenance for MM After ASCT
Peking University People's Hospital
Phase NA Recruiting
NCT05797948 2023-04-04
GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
The First Affiliated Hospital of Soochow University
Phase NA Unknown
NCT04432402 2020-06-16
Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase NA Unknown
NCT01927718 2019-04-29
Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)
M.D. Anderson Cancer Center
Phase NA Terminated
NCT01050790 2018-06-26
Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma
Virginia Commonwealth University
Phase NA Completed
NCT00890552 2017-03-22
A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis
Stanford University
Phase NA Completed
NCT02525250 2015-08-17
Pilot Study Immunomonitoring Natural Killers Cells in Patients With Myeloid Malignancies Treated With Lenalidomide
Institut Paoli-Calmettes
Phase NA Completed